Sodium Citrate

Drug Overview

Sodium Citrate represents a paradigm shift within the Nephrology and critical care specialties. Categorized under the Regional Anticoagulation drug class, it is currently the gold standard for maintaining the patency of extracorporeal circuits in critically ill patients. As an international health brand committed to advancing intensive care nephrology, we recognize Regional Citrate Anticoagulation (RCA) as an indispensable, localized Targeted Therapy. Unlike systemic blood thinners, Sodium Citrate confines its anticoagulant effect entirely within the dialysis machine, protecting highly vulnerable ICU patients from catastrophic bleeding complications.

• Generic Name: Trisodium Citrate, Sodium Citrate
• US Brand Names: Prismocitrate®, Regiocit® (specifically formulated CRRT replacement/anticoagulant fluids); ACD-A (Anticoagulant Citrate Dextrose Solution A)
• Drug Category: Nephrology
• Drug Class: Regional Anticoagulation / Calcium Chelators
• Route of Administration: Intravenous (Continuous pre-filter infusion into the extracorporeal circuit)
• FDA Approval Status: Fully FDA-approved for continuous renal replacement therapy (CRRT) anticoagulation, apheresis, and blood product preservation.

What Is It and How Does It Work? (Mechanism of Action)

To understand Sodium Citrate’s mechanism, one must first understand the role of ionized calcium in the human body. Ionized calcium (often referred to clinically as Factor IV) is an absolute, non-negotiable requirement for the human coagulation cascade. It acts as a necessary bridge for the assembly of the tenase and prothrombinase complexes on the surface of activated platelets.

At the molecular level, Sodium Citrate acts as a potent chelating agent. When infused into the arterial line of the dialysis circuit (blood leaving the patient), the citrate molecules rapidly bind to the free, ionized calcium (Ca^2+) in the plasma, forming a highly soluble calcium-citrate complex. This chelation aggressively strips the blood of its free calcium, dropping the ionized calcium levels within the circuit to profoundly low levels (typically < 0.35 mmol/L). Without free calcium, the coagulation cascade is completely paralyzed, and blood cannot clot within the artificial dialyzer fibers.

The brilliance of this Targeted Therapy lies in its regional nature. Before the blood is returned to the patient (post-filter), a separate infusion of Calcium Chloride or Calcium Gluconate is administered to replace the chelated calcium. This instantly restores the blood’s ability to clot just as it re-enters the patient’s systemic circulation. Furthermore, the calcium-citrate complexes that enter the patient’s body are rapidly metabolized by the liver, skeletal muscle, and renal cortex into bicarbonate, providing a buffering effect against metabolic acidosis.

FDA-Approved Clinical Indications

Primary Indication

• Preventing clotting only within the circuit during CRRT (ICU dialysis): Indicated as the first-line regional anticoagulant to maintain dialyzer patency during Continuous Venovenous Hemofiltration (CVVH), Hemodialysis (CVVHD), or Hemodiafiltration (CVVHDF) in critically ill patients, particularly those with a high risk of active bleeding.

Other Approved Uses

• Apheresis and Blood Collection: Used to prevent clotting during therapeutic plasma exchange (TPE) and the collection/storage of whole blood and blood components.
• Systemic Alkalinization: Orally administered (as potassium citrate/sodium citrate) to alkalinize urine for the dissolution of uric acid or cystine renal calculi.

Dosage and Administration Protocols

Sodium Citrate dosing during CRRT is highly complex, strictly protocol-driven, and governed by specialized software on modern CRRT machines. It requires a tandem continuous infusion of a calcium supplement to ensure patient safety.

Dose Adjustments and Specific Patient Populations:

• Hepatic Insufficiency: The most critical consideration for RCA. Citrate relies heavily on hepatic metabolism for clearance. In severe liver failure (e.g., cirrhosis, acute ischemic hepatitis/shock liver), citrate clearance drops drastically. The drug will accumulate in the systemic circulation, causing severe citrate toxicity. Dose reductions or alternative anticoagulation (like argatroban or no anticoagulation) may be required.
• Shock and Hypoxia: Patients with severe shock or lactic acidosis have impaired cellular metabolism, reducing their ability to clear the citrate load, requiring meticulous monitoring.

Clinical Efficacy and Research Results

Current international nephrology guidelines (KDIGO 2020–2026) strongly recommend Regional Citrate Anticoagulation over systemic unfractionated heparin as the first-line therapy for CRRT in patients without contraindications.

Recent large-scale multicenter trials demonstrate that RCA significantly outperforms heparin in maintaining circuit patency. Circuits utilizing optimal citrate protocols exhibit an average lifespan of >72 hours in up to 80% of cases, compared to 35-45 hours for heparin-based circuits. This superior patency drastically reduces the “down-time” of the dialysis machine, ensuring the patient receives the prescribed dose of continuous clearance. Most importantly, contemporary data shows that RCA reduces the incidence of systemic bleeding complications by approximately 60% compared to systemic heparin, directly contributing to improved ICU morbidity profiles and reduced requirements for blood transfusions.

Safety Profile and Side Effects

Important Safety Warning: While not carrying a Black Box Warning for CRRT use, Sodium Citrate must never be inadvertently infused directly into a patient without the accompanying CRRT circuit and strict monitoring. Direct, rapid systemic infusion will cause instantaneous, profound hypocalcemia leading to fatal cardiac arrhythmias and cardiovascular collapse.

Common Side Effects (>10%)

• Metabolic Alkalosis: Due to the hepatic conversion of citrate into bicarbonate, mild to moderate alkalinization is expected and usually managed by adjusting the CRRT dialysate/replacement fluid buffer concentrations.
• Mild Hypocalcemia: Transient drops in systemic ionized calcium due to under-replacement at the post-filter site.
• Hypomagnesemia: Citrate chelates magnesium as well as calcium, requiring routine magnesium supplementation.

Serious Adverse Events

• Citrate Toxicity (Citrate Accumulation): Occurs when the patient’s liver cannot metabolize the citrate load. Characterized by a rising Total Calcium but dropping Ionized Calcium (a Total-to-Ionized Calcium ratio > 2.5 is diagnostic).
• Severe Metabolic Acidosis: A paradoxical late sign of citrate toxicity where un-metabolized citrate accumulates, and lactic acidosis worsens due to cellular dysfunction.
• Severe Arrhythmias: Resulting from profound hypocalcemia or hypomagnesemia if the calcium replacement pump fails or is misprogrammed.

Management Strategies

• Metabolic Monitoring: Meticulous, scheduled measurements of systemic and circuit ionized calcium (usually every 4-6 hours) are non-negotiable.
• Toxicity Protocol: If the Total-to-Ionized calcium ratio exceeds 2.5, or if unexplained systemic hypocalcemia and worsening acidosis occur, the citrate infusion must be immediately reduced or stopped entirely, and the patient must be assessed for hepatic failure or severe shock.

Connection to Stem Cell and Regenerative Medicine

Sodium Citrate plays an indispensable, foundational role in modern Regenerative Medicine and cellular therapy. The entire field of hematopoietic stem cell transplantation (HSCT) relies on leukapheresis—a specialized extracorporeal process used to harvest peripheral blood stem cells (PBSCs) from donors or patients. During this continuous flow centrifugation process, regional Sodium Citrate (typically ACD-A) is the exclusive Biologic preserver and anticoagulant utilized. Because stem cells are highly sensitive to the mechanical stress and activation of the coagulation cascade inside the centrifuge, citrate’s gentle, reversible chelation ensures that the stem cells are harvested efficiently, remain viable, and do not clump. Without the specific regional properties of citrate, the large-scale collection of stem cells required for targeted oncological immunotherapies and regenerative tissue engineering would be practically impossible.

Patient Management and Practical Recommendations

Pre-Treatment Tests

• Comprehensive Metabolic Panel: Strict baseline assessment of Total Calcium, Magnesium, and Liver Function Tests (AST, ALT, Bilirubin).
• Ionized Calcium: Direct baseline measurement using an arterial blood gas (ABG) or venous blood gas (VBG) analyzer.
• Coagulation Profile: Baseline PT/INR, aPTT, and platelet count.

Precautions During Treatment

• Dedicated Lines: Post-filter calcium replacement must run through a dedicated, securely functioning intravenous lumen. If this line infiltrates or occludes, systemic hypocalcemia will develop rapidly.
• Ratio Surveillance: The ICU nursing staff and nephrology team must continuously calculate the Total Calcium to Ionized Calcium ratio to detect early signs of hepatic citrate accumulation.

Do’s and Don’ts

• (Note: Because CRRT is an ICU procedure, these are directed at the critical care/nephrology team handling the patient)
• DO check systemic (patient) ionized calcium and post-filter (circuit) ionized calcium strictly according to the facility’s timed protocol (e.g., 1 hour, 2 hours, and 6 hours after any dose adjustment).
• DO ensure the calcium replacement infusion is running correctly before starting the citrate blood pump.
• DO monitor the patient continuously on a cardiac telemetry monitor for QT-prolongation, an early ECG sign of hypocalcemia.
• DON’T use Regional Citrate Anticoagulation in patients with profound, irreversible acute liver failure without explicit, continuous expert oversight and severely reduced dose protocols.
• DON’T ignore a rising total calcium level accompanied by a dropping systemic ionized calcium level; this is the hallmark of citrate toxicity and requires immediate intervention.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment plan. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.